How Chinese Flotation Reagents Could Embed in Australian Spodumene

Australia pulls more lithium ore out of the ground than any other country on Earth. What it cannot do, at least not at scale, is turn that ore into battery-grade chemicals efficiently without borrowing someone else’s chemistry.

That someone, increasingly, is China. The quiet contradiction at the centre of the Australian lithium story is that the rock is here, but the know-how to unlock the metal inside it is drifting offshore.

A single Shandong-based manufacturer sits near the centre of this dynamic. Operating at roughly 50,000 tonnes of flotation reagent capacity a year and already supplying 27 Chinese-invested spodumene projects across Africa, the company is now looking at the world’s two largest spodumene mines, both of them in Western Australia.

That interest fits a pattern the industry already knows well: Chinese processing technology follows Chinese capital into lithium supply chains, one geography at a time. The role of Chinese flotation reagents in Australia is the next chapter.

This piece maps the specific company, the specific mines, and the specific structural reasons the dependency is moving upstream, so you can assess the risk with more precision than the broad “China controls refining” headline usually allows.

From lepidolite to spodumene to Africa: the track record behind the Australian push

Shandong Zhuocheng did not stumble into lithium. The company’s interest in Australian spodumene is the latest move in a sequence that has repeated, with discipline, for three decades.

Founded in 1995, the firm started by solving a domestic problem: China lacked commercially available cationic flotation collectors for iron ore. It built them. Then it moved up the value curve on a roughly ten-year rhythm.

• 1995, iron ore: entered to fill a gap in domestic collector supply, establishing the core chemistry capability
• Circa 2005, lepidolite: developed neutral to mildly alkaline collectors tuned for lithium oxide recovery, becoming the largest and most reliable supplier to China’s lepidolite sector, now serving at least 90 projects
• Circa 2015, spodumene: extended the same tailored approach to hard-rock lithium, supplying 27 Chinese-invested enterprises across Africa

The engine behind each step is a stated “one mine, one product” policy. Rather than selling a commodity reagent, the company customises the formulation to each specific deposit and re-tunes the mixture as the ore body changes over time.

The differentiator Shandong Zhuocheng’s “one mine, one product” approach means it is not competing on price for a generic chemical. It is selling deposit-specific optimisation, a model that travels well because every new mine is a fresh problem to solve.

The breadth is considerable. The company’s own corporate material states it has developed close to 20 flotation reagent types spanning spodumene, lepidolite, iron ore, magnesite, feldspar-quartz, fluorspar and other oxide ores. It holds ISO 9001, ISO 45001 and ISO 14001 certifications in quality, safety and environmental management.

Here is the detail that matters most for Australia. Lepidolite collector production is running near maximum, but spodumene collector capacity sits at roughly 50% utilisation.

That spare headroom is the signal. With African projects consuming only half of available spodumene reagent output, the company has both the proven track record and the physical capacity to absorb major new Australian accounts without building a single new line. For investors sizing up who the likely suppliers are before they become embedded, that readiness is the point: this is a proven operator arriving with a specific expansion logic, not an untested newcomer.

Why Australia’s spodumene giants are the obvious next market

Follow the production numbers and the strategic logic becomes self-evident. Any reagent supplier serious about the global spodumene sector eventually has to engage with two Western Australian operations, because the market has concentrated there.

Greenbushes and Pilgangoora are the two largest spodumene mines in the world. The University of Technology Sydney (UTS) describes Greenbushes as the “cornerstone” of Australian spodumene production, and the output data backs the label.

In calendar year 2025, Greenbushes produced 1.35 Mt of spodumene concentrate from 6.16 Mt of ore grading 1.9% Li₂O, against a nameplate capacity of 1.5 Mtpa. That accounted for 41% of Western Australia’s spodumene concentrate output on a lithium carbonate equivalent basis, up from 37% in 2024.

The Greenbushes production framework illustrates why scale and ore grade compound together at this deposit: running at 1.9% Li₂O against a nameplate of 1.5 Mtpa, the operation sets the technical benchmark that any upstream supplier must demonstrate compatibility with before gaining a foothold.

Pilgangoora closes the gap on scale

Pilbara Minerals’ Pilgangoora produced 755,000 t of concentrate in FY25, beating guidance of 700,000-740,000 t. After the P1000 expansion lifted nameplate capacity to 1 Mtpa, June-quarter 2025 output reached 221,300 t, a 77% quarter-on-quarter jump, at a unit operating cost of A$627/t.

The resource position is now the largest of any hard-rock lithium deposit: 446 Mt at 1.28% Li₂O, which overtook Greenbushes. Pilgangoora held 19% of WA output in 2025. One line, the 200,000 tpa Ngungaju plant, was idled, but the main lines kept running at scale.

Zoom out and the national picture confirms the concentration. Australia’s total lithium production was estimated at 113.5 kt in 2025, up 1.8% on 2024, and WA’s other lithium mines swung back to profitability in the final quarter of the year.

Together, these two mines account for 60% of WA’s spodumene output. For a reagent supplier, locking in supply at both would be the practical equivalent of capturing the Australian market. For anyone invested in Pilbara Minerals or exposed to the Greenbushes ownership chain, that scale is exactly what makes these assets the primary targets for upstream Chinese penetration.

Why Chinese reagent expertise keeps winning in new spodumene markets

The temptation is to read Chinese dominance as a simple cost story. That misreads the mechanism. What China has built is accumulated technical depth, and depth does not equalise just because a competitor shows up with cheaper inputs.

Three reinforcing structural mechanisms explain why Chinese reagent suppliers keep arriving first in new spodumene markets.

1. Scale and learning-by-doing: large domestic refining and processing clusters give Chinese reagent makers a home market to test and refine collectors, depressants and frothers across many ore bodies, compounding performance gains through sheer volume
2. Ore-type diversity: serving both lepidolite and spodumene, plus other oxide ores, forces reagent innovation against complex and varied mineralogy, which is precisely how a supplier builds close to 20 tailored reagent types
3. Integration with offtake chains: because Australian concentrate ships to China for refining, Chinese processors capture midstream margins and have a direct incentive to optimise recoveries at the flotation stage using locally supplied reagents

That third mechanism is the one Australian producers tend to underweight. China controls roughly 60% of global lithium refining capacity, and most Australian spodumene is exported there for conversion rather than refined at home. That alignment means a Chinese reagent supplier and a Chinese offtake operator are pulling in the same direction, and any Australian-sourced alternative would have to overcome that embedded relationship, not just match a price.

Lithium supply chain control concentrates at processing nodes rather than at the mine face, which is why the 60% refining share China holds translates into commercial leverage that starts well before a tonne of concentrate reaches a converter.

UTS draws the contrast sharply with South America’s Lithium Triangle, where brine is processed locally into battery-grade chemicals.

UTS analysis frames Australia’s reliance on Chinese refining as introducing geopolitical risk and limited value capture, leaving the country holding the ore while another jurisdiction holds the conversion technology.

A caveat on the evidence. No public figures quantify the size, revenue or market share of China’s flotation reagent sector, so this is a structural argument built on mechanisms rather than market-size data.

The 60% refining figure tells you where control of the value chain sits today. The reagent dynamic is the upstream layer of that same advantage, and it signals durability: this is a capability gap that deepens with every new project served, not a temporary edge that fades as markets mature.

What the reagent dependency means for Australian producers and investors right now

The refining dependency is well documented. The reagent layer adds distinct risks on top of it, and most of them are not yet on anyone’s radar.

• Supply-chain sovereignty: the dependency on Chinese processing know-how now extends upstream to the flotation stage, not just to refining
• Carbon leakage and ESG: UTS notes that refining emissions for Australian spodumene are generated in China, complicating any low-carbon claim and raising exposure to future carbon-border adjustments
• Policy vacuum: no identified post-2024 Australian regulatory instrument specifically governs Chinese flotation reagent imports or Chinese processing technology exports to Australia
• Economic value capture: conversion margins accrue in China, meaning Australia keeps less of the chain than it would with integrated refining

A policy response aimed at the wrong layer

Western Australian government policy has focused on building downstream battery industry capacity, the stated answer to the processing dependency. That ambition is sound, but it leaves the upstream reagent question unaddressed.

The WA Battery and Critical Minerals Strategy 2024-2030 sets out the state government’s objectives for capturing more value onshore through higher-value processing and manufacturing, yet the strategy’s focus on downstream battery manufacturing leaves the upstream flotation reagent question entirely unaddressed.

The practical consequence is that any Australian producer weighing a reagent supply agreement with a Chinese supplier is doing so without a regulatory framework around it. That absence is itself a risk factor, and one worth building into due diligence on any lithium asset.

Timing makes this live rather than theoretical. As of January 2026, Pilbara Minerals was evaluating a restart of the idled Ngungaju plant, with a board decision expected in the March quarter 2026. Mine-level investment calls are being made right now, which is exactly when reagent supply questions move from procurement detail to strategic consideration.

For investors in Australian spodumene producers, the reagent layer adds a dimension the headline refining story misses: it touches processing economics, ESG credentials and strategic resilience in a geopolitical environment that is not improving.

This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making investment decisions.

Before reagent supply lines harden: what Australian lithium stakeholders should watch

The useful question now is not whether the dependency exists but whether it is deepening or being managed. A handful of concrete signals will answer it.

1. Named supply agreements between Shandong Zhuocheng, or any peer Chinese supplier, and Greenbushes or Pilgangoora
2. A WA or federal policy instrument that specifically addresses upstream processing input sovereignty, not just downstream battery manufacturing
3. Alternative reagent development programmes emerging at the mine level, signalling a hedge against single-source dependence
4. Movement on domestic refining capacity that would shift offtake alignment away from China and weaken the integration advantage

Alternative spodumene processing chemistry emerging from research institutions represents the longer-horizon hedge against reagent dependency; MIT’s room-temperature closed-loop approach, if it scales, would sidestep the flotation stage where Chinese suppliers currently hold accumulated technical depth.

Domestic refining capacity represents the one structural shift that could materially alter offtake alignment, because Australian concentrate routed to a local converter no longer reinforces the reagent relationship that Chinese processors have an incentive to embed.

Watch how any engagement actually arrives. Shandong Zhuocheng’s African expansion followed Chinese investment into new geographies, which suggests Australian entry is more likely to progress through existing Chinese-affiliated networks at the two mines than through open tender.

The structural setup is already in place. Spodumene reagent capacity sits near 50% utilisation, and Greenbushes’ 41% and Pilgangoora’s 19% shares mark the exact points where a supply decision would ripple furthest. As of October 2026, the strategic direction is confirmed but no specific agreements have been disclosed publicly.

The sovereignty debate around Australian lithium has fixed on refining. The flotation reagent layer deserves the same scrutiny, because that is where the dependency may quietly deepen next.

If you track only the refining and conversion story, you risk missing the moment reagent supply shifts from a technical procurement question into a strategic dependency. That shift may already be underway at the mine level, and the watch-list above is how you will see it coming.

Past performance does not guarantee future results. Forward-looking statements are speculative and subject to change based on market developments, policy decisions and company performance.